Literature DB >> 8322708

Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas. An immunohistochemical study of 527 cases.

T S Loy1, S C Sharp, C J Andershock, S B Craig.   

Abstract

To determine the distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas, formalin-fixed paraffin-embedded tissue from 527 cases of these tumors was studied using a monoclonal antibody to CA 19-9 and an avidin-biotin immunohistochemical technique. Positive reactivity was seen in some tumors of all types except hepatocellular carcinoma. Positive reactions were most common in pancreatic adenocarcinomas (94%), bile duct carcinomas (91%), and transitional cell carcinomas (76%). The majority of tumors from the ovary, endometrium, distal esophagus/stomach, and colon also showed positive staining. Immunoreactivity was seen in 25-29% of carcinomas of the lung, thyroid, and endocervix. Few positive reactions were seen in renal cell carcinomas (2%), prostatic adenocarcinomas (3%), and breast carcinomas (6%). It was concluded that CA 19-9 is frequently present in several types of adenocarcinoma and transitional cell carcinoma. Immunostaining for CA 19-9 may be helpful in excluding hepatocellular carcinoma, prostatic adenocarcinoma, and renal cell carcinoma in certain clinical settings.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8322708     DOI: 10.1093/ajcp/99.6.726

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  15 in total

1.  Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.

Authors:  Jacob L Houghton; Brian M Zeglis; Dalya Abdel-Atti; Ritsuko Sawada; Wolfgang W Scholz; Jason S Lewis
Journal:  J Nucl Med       Date:  2015-10-15       Impact factor: 10.057

Review 2.  Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?

Authors:  Benjamin A Krantz; Eileen M O'Reilly
Journal:  Clin Cancer Res       Date:  2017-12-21       Impact factor: 12.531

Review 3.  Improving theranostics in pancreatic cancer.

Authors:  Jeremy King; Michael Bouvet; Gagandeep Singh; John Williams
Journal:  J Surg Oncol       Date:  2017-05-17       Impact factor: 3.454

Review 4.  Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas.

Authors:  Crystal S Seldon; Lauren E Colbert; William A Hall; Sarah B Fisher; David S Yu; Jerome C Landry
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

Review 5.  The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic.

Authors:  Thinzar M Lwin; Robert M Hoffman; Michael Bouvet
Journal:  Expert Rev Anticancer Ther       Date:  2018-05-28       Impact factor: 4.512

Review 6.  Current status and future perspectives of fluorescence-guided surgery for cancer.

Authors:  Jonathan C DeLong; Robert M Hoffman; Michael Bouvet
Journal:  Expert Rev Anticancer Ther       Date:  2015-12-07       Impact factor: 4.512

Review 7.  Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer.

Authors:  Willemieke S Tummers; Juergen K Willmann; Bert A Bonsing; Alexander L Vahrmeijer; Sanjiv S Gambhir; Rutger-Jan Swijnenburg
Journal:  Pancreas       Date:  2018-07       Impact factor: 3.327

8.  Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.

Authors:  Jacob L Houghton; Brian M Zeglis; Dalya Abdel-Atti; Robert Aggeler; Ritsuko Sawada; Brian J Agnew; Wolfgang W Scholz; Jason S Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-14       Impact factor: 11.205

9.  A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts.

Authors:  Matthew M Rochefort; Mark D Girgis; Scott M Knowles; Jacob S Ankeny; Felix Salazar; Anna M Wu; James S Tomlinson
Journal:  Mol Imaging Biol       Date:  2014-10       Impact factor: 3.488

10.  Imaging of primary and metastatic pancreatic cancer using a fluorophore-conjugated anti-CA19-9 antibody for surgical navigation.

Authors:  Michele McElroy; Sharmeela Kaushal; George A Luiken; Mark A Talamini; A R Moossa; Robert M Hoffman; Michael Bouvet
Journal:  World J Surg       Date:  2008-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.